A whole-genome CRISPR screen to investigate cisplatin resistance mechanisms in bladder cancer identified MSH2 as the most enriched gene and the mismatch repair pathway as the most significantly enriched pathway [97]. This evidence concerns the gene MSH2 and urinary bladder cancer.